Wockhardt wins Indian approval for novel antibiotic Zaynich
The regulator cleared Zaynich for complicated urinary tract infections, marking a shift for Wockhardt from generics to proprietary innovation.
— 1 earlier story on Wockhardt Ltd. →What's new
- CDSCO granted final marketing authorization for Zaynich to treat complicated urinary tract infections.
- The drug targets metallo-beta-lactamase-mediated resistance, a major clinical challenge in India.
- Wockhardt has pending marketing applications in the US and Europe with QIDP and Priority Review status.
Why this matters
This approval validates over 15 years of R&D and marks a pivot for Wockhardt away from its reliance on generics. By addressing a critical unmet need in antimicrobial resistance, the company gains a first-mover advantage in a high-barrier segment.
What we're watching
- The timeline for the domestic commercial launch.
- Progress on US and EU marketing applications.
- Impact on revenue composition as the company shifts toward innovative pharmaceuticals.
The full read
Wockhardt has secured final marketing authorization from the Central Drugs Standard Control Organisation for its novel antibiotic, Zaynich. The drug, which combines Zidebactam and Cefepime, is designed to treat complicated urinary tract infections and Gram-negative bacteremia. In its Phase 3 ENHANCE-1 study, Zaynich delivered a composite cure rate of 89%, statistically outperforming the 68% rate seen with the standard-of-care, meropenem. This approval is the result of 15 years of R&D and provides a solution for metallo-beta-lactamase-mediated resistance, a significant clinical hurdle in India. For a company with a market capitalization of ₹28,788 crore, this is a shift in business model. Wockhardt is moving away from its traditional generics base toward proprietary innovation. With US and EU applications already in progress under QIDP and Priority Review designations, the domestic launch is the first step in proving the commercial viability of its pipeline.
Questions answered
- What is Zaynich, and what does it treat?
- Zaynich is a novel antibiotic developed by Wockhardt that combines Zidebactam and Cefepime. It is approved for treating complicated urinary tract infections, including pyelonephritis and cases with concurrent Gram-negative bacteremia.
- How does Zaynich perform against current standards?
- In the Phase 3 ENHANCE-1 study, Zaynich achieved a composite cure rate of 89%, compared to 68% for the standard-of-care, meropenem.
- Why is this approval significant for Wockhardt?
- It represents the culmination of 15 years of R&D and marks the company's transition from a generics-focused business to an innovative pharmaceutical developer. The drug addresses a critical unmet need in India regarding antimicrobial resistance.
- What is the status of Zaynich in international markets?
- Wockhardt has submitted marketing applications in the US and Europe. The drug has already received Priority Review, Fast Track, and Qualified Infectious Disease Product designations from the FDA.
Story so far
All notes on WOCKPHARMA →- 28 May 2026 · 9:18 AM IST Wockhardt wins Indian approval for novel antibiotic Zaynich
- 7d ago Wockhardt's credit quality just improved — but the market already knew